根治性放疗肺癌患者治疗后淋巴细胞减少、全身积分剂量与总生存
该回顾性研究纳入217例接受根治性放疗的肺癌患者(131例非小细胞肺癌、86例小细胞肺癌),分析治疗后绝对淋巴细胞计数(ALC)与全身积分剂量及总生存(OS)的关系。多因素分析证实治疗前ALC、全身积分剂量和同步化疗是治疗后ALC的显著预测因素,低治疗后ALC、高治疗前中性粒细胞计数、高计划靶区积分剂量和较少分次数预测更差OS。
要点
- 治疗后中性粒细胞计数和ALC均显著下降(p < 0.001)。
- 治疗前ALC、全身积分剂量和同步化疗是治疗后ALC的显著预测因素(R²=0.33)。
- 低治疗后ALC、高治疗前中性粒细胞计数、高计划靶区积分剂量和较少分次数预测更差OS。
核心结论
- 全身积分剂量与治疗后ALC呈负相关,且治疗后ALC是接受根治性放疗肺癌患者的不良预后因素。
研究设计与样本
- 回顾性收集217例接受根治性放疗的肺癌患者(131例非小细胞肺癌和86例小细胞肺癌)的临床病理变量、剂量学参数及治疗前后血常规数据。
- 89例(42%)接受诱导化疗后放疗,99例(47%)接受同步放化疗。
- 分别对ALC和中性粒细胞计数进行多元逐步回归分析以建立治疗后计数预测模型,并使用Cox回归模型对OS进行多因素分析。
主要发现
- 治疗后中性粒细胞计数和ALC均较治疗前显著下降(p < 0.001)。
- 多元逐步线性回归分析显示,治疗前ALC、全身积分剂量和同步化疗的使用是治疗后ALC的显著预测因素(R²=0.33,F(4,212)=26.6,p < 0.001)。
- 治疗前中性粒细胞计数、心脏积分剂量和分次数是治疗后中性粒细胞计数的显著预测因素(R²=0.18,F(3,213)=16.38,p < 0.001)。
- 低治疗后ALC、高治疗前中性粒细胞计数、高计划靶区积分剂量和较少分次数预测更差OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Post-treatment lymphocytopaenia is a recognized complication of thoracic radiotherapy likely due to irradiation of a large volume of circulatory blood. We hypothesize that post-treatment absolute lymphocyte count (ALC) is associated with integral body dose and overall survival (OS) in lung cancer patients treated with radical radiotherapy. MATERIALS AND METHODS: Data on clinicopathological variables, dosimetric parameters, and pre and post-treatment blood counts were collected retrospectively in 217 lung cancer patients (131 with non-small cell lung cancer and 86 with small cell lung cancer) treated with radical radiotherapy. Induction chemotherapy followed by radiotherapy and concurrent chemoradiotherapy were delivered in 89 (42%) and 99 (47%) patients respectively. Multiple stepwise regression analysis was performed separately for ALC and absolute neutrophil count (ANC) to derive a model for prediction of post-treatment count and multivariate analysis was performed for OS using a Cox regression model. RESULTS: There was a significant decline in post-treatment counts for both ANC and ALC (p < 0.001). Multiple stepwise linear regression analysis confirmed pre-treatment ALC, body integral dose and use of concurrent chemotherapy as significant predictors of post-treatment ALC (R2 = 0.33, F(4,212) = 26.6 p < 0.001). Pre-treatment ANC, integral heart dose and number of fractions were significant predictors of post-treatment ANC (R2 = 0.18, F(3,213) = 16.38 p < 0.001). Low post-treatment ALC, high pre-treatment ANC, high planning target volume integral dose and lower number of fractions were predictive of inferior OS. CONCLUSIONS: There is a negative correlation between integral body dose and post-treatment ALC which is an adverse prognostic factor in lung cancer patients treated with radical radiotherapy.
引用
- Joseph N, McWilliam A, Kennedy J, et al. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. Radiother Oncol. 2019. PMID: 31015156. doi:10.1016/j.radonc.2019.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。